AKO-001
Pharmaceutical compound
From Wikipedia, the free encyclopedia
AKO-001, or AKO001, is a combination of the non-selective serotonin receptor agonist and serotonergic psychedelic dimethyltryptamine (DMT) and an undisclosed "specific plant bioactive" which is under development for the treatment of stroke.[1][2][3] While the "specific plant bioactive" in the combination and the action of this compound have not been disclosed, certain plant compounds, such as the β-carboline harmine in Banisteriopsis caapi, are reversible monoamine oxidase A (MAO-A) inhibitors and inhibit the metabolism of DMT, in turn greatly potentiating DMT and allowing it to become orally active.[4][5][6] AKO-001 is being developed by Akome Biotech.[1][2][3] As of March 2022, the drug is in the preclinical research stage of development.[1][2][3]
| Combination of | |
|---|---|
| Dimethyltryptamine | Serotonergic psychedelic |
| ? Component | Undisclosed specific plant bioactive |
| Clinical data | |
| Other names | AKO001; Dimethyltryptamine/specific plant bioactive; DMT/specific plant bioactive |
